PubMed · 8189564
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
I Goldstein. 1994. Impotence.. https://doi.org/10.1016/s0022-5347(17)35294-1
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Explore the source record for details and available documents.
PURPOSE: We attempted to identify risk factors for penile scarring in patients using prostaglandin E1 injection therapy. MATERIALS AND METHODS: Records of 92 patients using prostaglandin E1 therapeutically were reviewed. With statistical methods, patients with (15) and without (77) scarring were compared. RESULTS: No significant differences between the 2 groups were found regarding duration of followup, injection frequency, prostaglandin E1 dose per injection, total number of injections or total prostaglandin E1 dose. Patients with initial penile scarring did not have a significantly higher incidence of further scarring with prostaglandin E1. CONCLUSIONS: Penile scarring with prostaglandin E1 injection therapy is sporadic and unpredictable. Patients with initial penile scarring do not have a higher incidence of further scarring.
Neutrophil apoptosis, determined after 20 h in culture using standard criteria and shedding of cell surface CD16 (Fc gamma RIII), is dramatically inhibited, in a concentration-dependent manner, by the cAMP analogs, dibutyryl-cAMP and 8-Br-cAMP, and the adenylyl cyclase activator, forskolin. Furthermore, the stable receptor-directed PGD2 mimetic, ZK 118.182, and the PGE2 mimetic, 11-deoxy PGE1, similarly inhibited apoptosis. The DP-receptor antagonist BW A868C blocked the effect of ZK 118.182 and the protein kinase A inhibitor H-89 reversed the inhibition of apoptosis induced by dibutyryl-cAMP. These results clearly show that neutrophil apoptosis is markedly attenuated by cAMP elevating agents. This nucleotide second messenger may play a fundamental role in controlling neutrophil longevity and pharmacological regulation of cAMP levels or actions may influence neutrophil apoptosis in vivo.